Given that there is an actual product, and given the background and capabilities of the management team, it is far more likely to be the latter than the former.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025